- Home
- AYRO vs GLMD Comparison
AYRO vs GLMD Comparison
Compare AYRO & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYRO
- GLMD
- Stock Information
- Founded
- AYRO 2017
- GLMD 2000
- Country
- AYRO United States
- GLMD Israel
- Employees
- AYRO N/A
- GLMD N/A
- Industry
- AYRO Telecommunications Equipment
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- AYRO Consumer Discretionary
- GLMD Health Care
- Exchange
- AYRO Nasdaq
- GLMD Nasdaq
- Market Cap
- AYRO 4.8M
- GLMD 4.5M
- IPO Year
- AYRO N/A
- GLMD 2014
- Fundamental
- Price
- AYRO $0.59
- GLMD $2.70
- Analyst Decision
- AYRO
- GLMD
- Analyst Count
- AYRO 0
- GLMD 0
- Target Price
- AYRO N/A
- GLMD N/A
- AVG Volume (30 Days)
- AYRO 223.6K
- GLMD 21.6K
- Earning Date
- AYRO 03-31-2025
- GLMD 04-03-2025
- Dividend Yield
- AYRO N/A
- GLMD N/A
- EPS Growth
- AYRO N/A
- GLMD N/A
- EPS
- AYRO N/A
- GLMD N/A
- Revenue
- AYRO $221,671.00
- GLMD N/A
- Revenue This Year
- AYRO $2,424.87
- GLMD N/A
- Revenue Next Year
- AYRO N/A
- GLMD N/A
- P/E Ratio
- AYRO N/A
- GLMD N/A
- Revenue Growth
- AYRO N/A
- GLMD N/A
- 52 Week Low
- AYRO $0.49
- GLMD $2.24
- 52 Week High
- AYRO $1.83
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- AYRO 39.78
- GLMD 49.41
- Support Level
- AYRO $0.49
- GLMD $2.24
- Resistance Level
- AYRO $0.85
- GLMD $2.72
- Average True Range (ATR)
- AYRO 0.06
- GLMD 0.20
- MACD
- AYRO -0.00
- GLMD 0.02
- Stochastic Oscillator
- AYRO 28.33
- GLMD 71.47
About AYRO AYRO Inc.
AYRO Inc design and manufacture compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, which is the design, development, manufacturing, and sales of electric vehicles, and operates in the United States.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.